Hormone‑free male contraceptive under clinical investigation
YourChoice Therapeutics is developing the first oral hormone-free male contraceptive
Explore the science
See studies
YCT‑529 is an investigational agent. We do not claim that it is safe or effective for any use.
Why we are working on this
Men have two options: condoms or vasectomy. Neither is ideal.
Both partners want to share responsibility. Men just need real options.
YCT-529 is a non-hormonal, fully reversible pill with no testosterone changes.
Biology we are studying
YCT‑529 is designed to selectively block retinoic acid receptor‑alpha (RAR‑alpha). RAR‑alpha is fundamental for spermatogenesis (sperm production)
Our clinical program is evaluating whether modulating this pathway is acceptable from a safety and pharmacology perspective in humans
Because YCT‑529 is investigational, it has not been determined to be safe or effective by the U.S. Food and Drug Administration or any regulatory authority. We share source materials through peer‑reviewed publications and official study registries so readers can examine methods and data directly.
Program status
YCT‑529 — oral, non‑hormonal male contraception (investigational)
Clinical studies underway
Focus areas include safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD)
Anticipated timelines are subject to change.
YCT‑529 is investigational; no claims of safety or efficacy are made.
Clinical studies of YCT‑529
We sponsor and collaborate on clinical studies to evaluate YCT‑529. For official listings and status, please refer to our entries on ClinicalTrials.gov.
Reach out to us at
clinicaltrials@yourchoicetx.com
View registry entry
Publications and presentations
We share our research through peer‑reviewed publications and scientific meetings
The Lancet Editors, Towards gender equity in contraception: male contraceptive passes safety trial. eBioMedicine 119:105938 (2025).
Mannowetz, N., Chung, S.S.W., Maitra, S. et al. Targeting the retinoid signaling pathway with YCT‑529 for effective and reversible oral contraception in mice and primates. Commun Med 5, 68 (2025)
Mannowetz, N., McCallum, S.W., Sidhu, S. et al. Safety and pharmacokinetics of the non‑hormonal male contraceptive YCT‑529. Commun Med 5, 279 (2025)
Md Abdullah, A.N., Cuellar, R.A.D., Kyzer, J.L. et al. Strategies for developing retinoic acid receptor alpha‑selective antagonists as novel agents for male contraception. Eur J Med Chem 261: 115821 (2023),
Taher, N., Haque, E. and Georg, I.G. From concept to the clinic: Retinoic acid receptor alpha antagonist YCT‑529, an oral non‑hormonal male contraceptive. Andrology (2025).
Shi, R., Wolgemuth, D.J., Georg, I.G. Development of the retinoic acid receptor alpha‑specific antagonist YCT‑529 for male contraception: A brief review. Contraception 145 (2025).
Founders
Akash Bakshi, MSc
Co‑founder & CEO
Nadja Mannowetz, PhD
Co‑founder & CSO
Open roles
Newsroom
Company updates and selected media coverage
Bloomberg Businessweek - The Future of Male Birth Control Could Be Pills, Gels and Implants - January 28, 2026
Scientific American - Male Birth Control Pill YCT‑529 Passes Human Safety Test - Jul 22, 2025
Reuters (Health Rounds) - Birth control pill for men moves closer to reality - Mar 14, 2025
STAT News - Male birth control pill enters Phase 1 trial in U.K. - Dec 13, 2023
The Times (UK) - Male contraceptive pill ‘found to be safe’ in trials - Aug 2025
The Independent - Male contraceptive pill appears to be safe without side effects, trial finds - Aug 5, 2025
Live Science - Male birth control pill passes early safety test, with more trials underway - Jul 2025
ACS Chemical & Engineering News - Birth control for men - Nov 21, 2022
Medscape - First Hormone‑Free Male Pill? YCT‑529 Shows Early Promise - May 20, 2025
University of Minnesota (Twin Cities) - First hormone‑free male birth control pill clears another milestone - Mar 26, 2025
UMN College of Pharmacy - Male birth control pill shows promise in clinical trials - Aug 1, 2025
Press releases
Business Wire — YourChoice Therapeutics Announces Nature Publication — Mar 13, 2025
Business Wire — YourChoice Therapeutics announces second Nature publication — Jul 22, 2025
Boilerplate (for press uses)
YourChoice Therapeutics is developing hormone‑free, oral investigational male contraception. YCT‑529 is a selective retinoic‑acid receptor‑alpha (RAR‑alpha) antagonist under clinical investigation and has not been approved by any regulatory authority.
Investor access
Request access to our investor materials. Investor information is shared at our discretion and may require a confidentiality agreement.
Request investor access
Hormone‑free male contraceptive under clinical investigation
YourChoice Therapeutics is developing the first oral hormone-free male contraceptive.
YCT‑529 is an investigational agent. We do not claim that it is safe or effective for any use.
Why we are working on this
Men have two options: condoms or vasectomy. Neither is ideal.
Both partners want to share responsibility. Men just need real options.
YCT-529 is a non-hormonal, fully reversible pill with no testosterone changes.
Biology we are studying
YCT‑529 is designed to selectively block retinoic acid receptor‑alpha (RAR‑alpha). RAR‑alpha is fundamental for spermatogenesis (sperm production)
Our clinical program is evaluating whether modulating this pathway is acceptable from a safety and pharmacology perspective in humans
Because YCT‑529 is investigational, it has not been determined to be safe or effective by the U.S. Food and Drug Administration or any regulatory authority. We share source materials through peer‑reviewed publications and official study registries so readers can examine methods and data directly.
Program status
YCT‑529 — oral, non‑hormonal male contraception (investigational)
Clinical studies underway
Focus areas include safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD)
Anticipated timelines are subject to change.
YCT‑529 is investigational; no claims of safety or efficacy are made.
Clinical studies of YCT‑529
We sponsor and collaborate on clinical studies to evaluate YCT‑529. For official listings and status, please refer to our entries on ClinicalTrials.gov.
Reach out to us at
clinicaltrials@yourchoicetx.com
View registry entry
Publications and presentations
We share our research through peer‑reviewed publications and scientific meetings
The Lancet Editors, Towards gender equity in contraception: male contraceptive passes safety trial. eBioMedicine 119:105938 (2025).
Mannowetz, N., Chung, S.S.W., Maitra, S. et al. Targeting the retinoid signaling pathway with YCT‑529 for effective and reversible oral contraception in mice and primates. Commun Med 5, 68 (2025)
Mannowetz, N., McCallum, S.W., Sidhu, S. et al. Safety and pharmacokinetics of the non‑hormonal male contraceptive YCT‑529. Commun Med 5, 279 (2025)
Md Abdullah, A.N., Cuellar, R.A.D., Kyzer, J.L. et al. Strategies for developing retinoic acid receptor alpha‑selective antagonists as novel agents for male contraception. Eur J Med Chem 261: 115821 (2023),
Taher, N., Haque, E. and Georg, I.G. From concept to the clinic: Retinoic acid receptor alpha antagonist YCT‑529, an oral non‑hormonal male contraceptive. Andrology (2025).
Shi, R., Wolgemuth, D.J., Georg, I.G. Development of the retinoic acid receptor alpha‑specific antagonist YCT‑529 for male contraception: A brief review. Contraception 145 (2025).
Founders
Akash Bakshi, MSc
Co‑founder & CEO
Nadja Mannowetz, PhD
Co‑founder & CSO
Open roles
Newsroom
Company updates and selected media coverage
Bloomberg Businessweek - The Future of Male Birth Control Could Be Pills, Gels and Implants - January 28, 2026
Scientific American - Male Birth Control Pill YCT‑529 Passes Human Safety Test - Jul 22, 2025
Reuters (Health Rounds) - Birth control pill for men moves closer to reality - Mar 14, 2025
STAT News - Male birth control pill enters Phase 1 trial in U.K. - Dec 13, 2023
The Times (UK) - Male contraceptive pill ‘found to be safe’ in trials - Aug 2025
The Independent - Male contraceptive pill appears to be safe without side effects, trial finds - Aug 5, 2025
Live Science - Male birth control pill passes early safety test, with more trials underway - Jul 2025
ACS Chemical & Engineering News - Birth control for men - Nov 21, 2022
Medscape - First Hormone‑Free Male Pill? YCT‑529 Shows Early Promise - May 20, 2025
University of Minnesota (Twin Cities) - First hormone‑free male birth control pill clears another milestone - Mar 26, 2025
UMN College of Pharmacy - Male birth control pill shows promise in clinical trials - Aug 1, 2025
Bloomberg Businessweek - The Future of Male Birth Control Could Be Pills, Gels and Implants - January 28, 2026
Press releases
Business Wire — YourChoice Therapeutics Announces Nature Publication — Mar 13, 2025
Business Wire — YourChoice Therapeutics announces second Nature publication — Jul 22, 2025
Boilerplate (for press uses)
YourChoice Therapeutics is developing hormone‑free, oral investigational male contraception. YCT‑529 is a selective retinoic‑acid receptor‑alpha (RAR‑alpha) antagonist under clinical investigation and has not been approved by any regulatory authority.
Investor access
Request access to our investor materials. Investor information is shared at our discretion and may require a confidentiality agreement.
Request investor access
Hormone‑free male contraceptive under clinical investigation
YourChoice Therapeutics is developing the first oral hormone-free male contraceptive.
YCT‑529 is an investigational agent. We do not claim that it is safe or effective for any use.
Why we are working on this
Men have two options: condoms or vasectomy. Neither is ideal.
Both partners want to share responsibility. Men just need real options.
YCT-529 is a non-hormonal, fully reversible pill with no testosterone changes.
Biology we are studying
YCT‑529 is designed to selectively block retinoic acid receptor‑alpha (RAR‑alpha). RAR‑alpha is fundamental for spermatogenesis (sperm production)
Our clinical program is evaluating whether modulating this pathway is acceptable from a safety and pharmacology perspective in humans
Because YCT‑529 is investigational, it has not been determined to be safe or effective by the U.S. Food and Drug Administration or any regulatory authority. We share source materials through peer‑reviewed publications and official study registries so readers can examine methods and data directly.
Program status
YCT‑529 — oral, non‑hormonal male contraception (investigational)
Clinical studies underway
Focus areas include safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD)
Anticipated timelines are subject to change.
YCT‑529 is investigational; no claims of safety or efficacy are made.
Clinical studies of YCT‑529
We sponsor and collaborate on clinical studies to evaluate YCT‑529. For official listings and status, please refer to our entries on ClinicalTrials.gov.
Reach out to us at
clinicaltrials@yourchoicetx.com
View registry entry
Publications and presentations
We share our research through peer‑reviewed publications and scientific meetings
The Lancet Editors, Towards gender equity in contraception: male contraceptive passes safety trial. eBioMedicine 119:105938 (2025).
Mannowetz, N., Chung, S.S.W., Maitra, S. et al. Targeting the retinoid signaling pathway with YCT‑529 for effective and reversible oral contraception in mice and primates. Commun Med 5, 68 (2025)
Mannowetz, N., McCallum, S.W., Sidhu, S. et al. Safety and pharmacokinetics of the non‑hormonal male contraceptive YCT‑529. Commun Med 5, 279 (2025)
Md Abdullah, A.N., Cuellar, R.A.D., Kyzer, J.L. et al. Strategies for developing retinoic acid receptor alpha‑selective antagonists as novel agents for male contraception. Eur J Med Chem 261: 115821 (2023),
Taher, N., Haque, E. and Georg, I.G. From concept to the clinic: Retinoic acid receptor alpha antagonist YCT‑529, an oral non‑hormonal male contraceptive. Andrology (2025).
Shi, R., Wolgemuth, D.J., Georg, I.G. Development of the retinoic acid receptor alpha‑specific antagonist YCT‑529 for male contraception: A brief review. Contraception 145 (2025).
Founders
Akash Bakshi, MSc
Co‑founder & CEO
Nadja Mannowetz, PhD
Co‑founder & CSO
Open roles
Newsroom
Company updates and selected media coverage
Bloomberg Businessweek - The Future of Male Birth Control Could Be Pills, Gels and Implants - January 28, 2026
Scientific American - Male Birth Control Pill YCT‑529 Passes Human Safety Test - Jul 22, 2025
Reuters (Health Rounds) - Birth control pill for men moves closer to reality - Mar 14, 2025
STAT News - Male birth control pill enters Phase 1 trial in U.K. - Dec 13, 2023
The Times (UK) - Male contraceptive pill ‘found to be safe’ in trials - Aug 2025
The Independent - Male contraceptive pill appears to be safe without side effects, trial finds - Aug 5, 2025
Live Science - Male birth control pill passes early safety test, with more trials underway - Jul 2025
ACS Chemical & Engineering News - Birth control for men - Nov 21, 2022
Medscape - First Hormone‑Free Male Pill? YCT‑529 Shows Early Promise - May 20, 2025
University of Minnesota (Twin Cities) - First hormone‑free male birth control pill clears another milestone - Mar 26, 2025
UMN College of Pharmacy - Male birth control pill shows promise in clinical trials - Aug 1, 2025
Press releases
Business Wire — YourChoice Therapeutics Announces Nature Publication — Mar 13, 2025
Business Wire — YourChoice Therapeutics announces second Nature publication — Jul 22, 2025
Boilerplate (for press uses)
YourChoice Therapeutics is developing hormone‑free, oral investigational male contraception. YCT‑529 is a selective retinoic‑acid receptor‑alpha (RAR‑alpha) antagonist under clinical investigation and has not been approved by any regulatory authority.
Investor access
Request access to our investor materials. Investor information is shared at our discretion and may require a confidentiality agreement.
Request investor access
Hormone‑free male contraceptive under clinical investigation
YourChoice Therapeutics is developing the first oral hormone-free male contraceptive.
YCT‑529 is an investigational agent. We do not claim that it is safe or effective for any use.
Why we are working on this
Men have two options: condoms or vasectomy. Neither is ideal.
Both partners want to share responsibility. Men just need real options.
YCT-529 is a non-hormonal, fully reversible pill with no testosterone changes.
Biology we are studying
YCT‑529 is designed to selectively block retinoic acid receptor‑alpha (RAR‑alpha). RAR‑alpha is fundamental for spermatogenesis (sperm production)
Our clinical program is evaluating whether modulating this pathway is acceptable from a safety and pharmacology perspective in humans
Because YCT‑529 is investigational, it has not been determined to be safe or effective by the U.S. Food and Drug Administration or any regulatory authority. We share source materials through peer‑reviewed publications and official study registries so readers can examine methods and data directly.
Program status
YCT‑529 — oral, non‑hormonal male contraception (investigational)
Clinical studies underway
Focus areas include safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD)
Anticipated timelines are subject to change.
YCT‑529 is investigational; no claims of safety or efficacy are made.
Clinical studies of YCT‑529
We sponsor and collaborate on clinical studies to evaluate YCT‑529. For official listings and status, please refer to our entries on ClinicalTrials.gov.
Reach out to us at
clinicaltrials@yourchoicetx.com
View registry entry
Publications and presentations
We share our research through peer‑reviewed publications and scientific meetings
The Lancet Editors, Towards gender equity in contraception: male contraceptive passes safety trial. eBioMedicine 119:105938 (2025).
Mannowetz, N., Chung, S.S.W., Maitra, S. et al. Targeting the retinoid signaling pathway with YCT‑529 for effective and reversible oral contraception in mice and primates. Commun Med 5, 68 (2025)
Mannowetz, N., McCallum, S.W., Sidhu, S. et al. Safety and pharmacokinetics of the non‑hormonal male contraceptive YCT‑529. Commun Med 5, 279 (2025)
Md Abdullah, A.N., Cuellar, R.A.D., Kyzer, J.L. et al. Strategies for developing retinoic acid receptor alpha‑selective antagonists as novel agents for male contraception. Eur J Med Chem 261: 115821 (2023),
Taher, N., Haque, E. and Georg, I.G. From concept to the clinic: Retinoic acid receptor alpha antagonist YCT‑529, an oral non‑hormonal male contraceptive. Andrology (2025).
Shi, R., Wolgemuth, D.J., Georg, I.G. Development of the retinoic acid receptor alpha‑specific antagonist YCT‑529 for male contraception: A brief review. Contraception 145 (2025).
Founders
Akash Bakshi, MSc
Co‑founder & CEO
Nadja Mannowetz, PhD
Co‑founder & CSO
Open roles
Newsroom
Company updates and selected media coverage
Bloomberg Businessweek - The Future of Male Birth Control Could Be Pills, Gels and Implants - January 28, 2026
Scientific American - Male Birth Control Pill YCT‑529 Passes Human Safety Test - Jul 22, 2025
Reuters (Health Rounds) - Birth control pill for men moves closer to reality - Mar 14, 2025
STAT News - Male birth control pill enters Phase 1 trial in U.K. - Dec 13, 2023
The Times (UK) - Male contraceptive pill ‘found to be safe’ in trials - Aug 2025
The Independent - Male contraceptive pill appears to be safe without side effects, trial finds - Aug 5, 2025
Live Science - Male birth control pill passes early safety test, with more trials underway - Jul 2025
ACS Chemical & Engineering News - Birth control for men - Nov 21, 2022
Medscape - First Hormone‑Free Male Pill? YCT‑529 Shows Early Promise - May 20, 2025
University of Minnesota (Twin Cities) - First hormone‑free male birth control pill clears another milestone - Mar 26, 2025
UMN College of Pharmacy - Male birth control pill shows promise in clinical trials - Aug 1, 2025
Press releases
Business Wire — YourChoice Therapeutics Announces Nature Publication — Mar 13, 2025
Business Wire — YourChoice Therapeutics announces second Nature publication — Jul 22, 2025
Boilerplate (for press uses)
YourChoice Therapeutics is developing hormone‑free, oral investigational male contraception. YCT‑529 is a selective retinoic‑acid receptor‑alpha (RAR‑alpha) antagonist under clinical investigation and has not been approved by any regulatory authority.
Investor access
Request access to our investor materials. Investor information is shared at our discretion and may require a confidentiality agreement.
Request investor access
Hormone‑free male contraceptive under clinical investigation
YourChoice Therapeutics is developing the first oral hormone-free male contraceptive.
YCT‑529 is an investigational agent. We do not claim that it is safe or effective for any use.
Why we are working on this
Men have two options: condoms or vasectomy. Neither is ideal.
Both partners want to share responsibility. Men just need real options.
YCT-529 is a non-hormonal, fully reversible pill with no testosterone changes.
Biology we are studying
YCT‑529 is designed to selectively block retinoic acid receptor‑alpha (RAR‑alpha). RAR‑alpha is fundamental for spermatogenesis (sperm production)
Our clinical program is evaluating whether modulating this pathway is acceptable from a safety and pharmacology perspective in humans
Because YCT‑529 is investigational, it has not been determined to be safe or effective by the U.S. Food and Drug Administration or any regulatory authority. We share source materials through peer‑reviewed publications and official study registries so readers can examine methods and data directly.
Program status
YCT‑529 — oral, non‑hormonal male contraception (investigational)
Clinical studies underway
Focus areas include safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD)
Anticipated timelines are subject to change.
YCT‑529 is investigational; no claims of safety or efficacy are made.
Clinical studies of YCT‑529
We sponsor and collaborate on clinical studies to evaluate YCT‑529. For official listings and status, please refer to our entries on ClinicalTrials.gov.
Reach out to us at
clinicaltrials@yourchoicetx.com
View registry entry
Publications and presentations
We share our research through peer‑reviewed publications and scientific meetings
The Lancet Editors, Towards gender equity in contraception: male contraceptive passes safety trial. eBioMedicine 119:105938 (2025).
Mannowetz, N., Chung, S.S.W., Maitra, S. et al. Targeting the retinoid signaling pathway with YCT‑529 for effective and reversible oral contraception in mice and primates. Commun Med 5, 68 (2025)
Mannowetz, N., McCallum, S.W., Sidhu, S. et al. Safety and pharmacokinetics of the non‑hormonal male contraceptive YCT‑529. Commun Med 5, 279 (2025)
Md Abdullah, A.N., Cuellar, R.A.D., Kyzer, J.L. et al. Strategies for developing retinoic acid receptor alpha‑selective antagonists as novel agents for male contraception. Eur J Med Chem 261: 115821 (2023),
Taher, N., Haque, E. and Georg, I.G. From concept to the clinic: Retinoic acid receptor alpha antagonist YCT‑529, an oral non‑hormonal male contraceptive. Andrology (2025).
Shi, R., Wolgemuth, D.J., Georg, I.G. Development of the retinoic acid receptor alpha‑specific antagonist YCT‑529 for male contraception: A brief review. Contraception 145 (2025).
Founders
Akash Bakshi, MSc
Co‑founder & CEO
Nadja Mannowetz, PhD
Co‑founder & CSO
Open roles
Newsroom
Company updates and selected media coverage
Bloomberg Businessweek - The Future of Male Birth Control Could Be Pills, Gels and Implants - January 28, 2026
Scientific American - Male Birth Control Pill YCT‑529 Passes Human Safety Test - Jul 22, 2025
Reuters (Health Rounds) - Birth control pill for men moves closer to reality - Mar 14, 2025
STAT News - Male birth control pill enters Phase 1 trial in U.K. - Dec 13, 2023
The Times (UK) - Male contraceptive pill ‘found to be safe’ in trials - Aug 2025
The Independent - Male contraceptive pill appears to be safe without side effects, trial finds - Aug 5, 2025
Live Science - Male birth control pill passes early safety test, with more trials underway - Jul 2025
ACS Chemical & Engineering News - Birth control for men - Nov 21, 2022
Medscape - First Hormone‑Free Male Pill? YCT‑529 Shows Early Promise - May 20, 2025
University of Minnesota (Twin Cities) - First hormone‑free male birth control pill clears another milestone - Mar 26, 2025
UMN College of Pharmacy - Male birth control pill shows promise in clinical trials - Aug 1, 2025
Press releases
Business Wire — YourChoice Therapeutics Announces Nature Publication — Mar 13, 2025
Business Wire — YourChoice Therapeutics announces second Nature publication — Jul 22, 2025
Boilerplate (for press uses)
YourChoice Therapeutics is developing hormone‑free, oral investigational male contraception. YCT‑529 is a selective retinoic‑acid receptor‑alpha (RAR‑alpha) antagonist under clinical investigation and has not been approved by any regulatory authority.
Investor access
Request access to our investor materials. Investor information is shared at our discretion and may require a confidentiality agreement.
Request investor access